iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at Wedbush in a research note issued on Monday,RTT News reports. They currently have a $10.50 price objective on the stock, down from their previous price objective of $12.00. Wedbush's price objective suggests a potential upside of 3.70% from the company's current price.

A number of other analysts also recently commented on the company. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Wells Fargo & Company restated an "equal weight" rating and set a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Piper Sandler restated an "overweight" rating and set a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs cut shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Finally, Raymond James Financial set a $12.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, iTeos Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $15.64.

iTeos Therapeutics Price Performance

ITOS traded up $0.01 during trading on Monday, hitting $10.13. The company's stock had a trading volume of 745,635 shares, compared to its average volume of 765,140. The firm's 50 day moving average price is $9.63 and its 200-day moving average price is $7.93. The stock has a market cap of $387.48 million, a PE ratio of -3.33 and a beta of 1.49. iTeos Therapeutics has a twelve month low of $4.80 and a twelve month high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. Equities analysts anticipate that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michel Detheux sold 43,883 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the transaction, the chief executive officer owned 153,903 shares of the company's stock, valued at approximately $1,542,108.06. This trade represents a 22.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David Hallal sold 38,228 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.24, for a total transaction of $391,454.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,939,307 shares of company stock worth $16,202,116. Corporate insiders own 12.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN grew its stake in iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after buying an additional 2,402 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after buying an additional 3,293 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in iTeos Therapeutics by 5.0% in the 4th quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company's stock valued at $530,000 after buying an additional 3,305 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in iTeos Therapeutics by 25.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company's stock valued at $103,000 after buying an additional 3,468 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in iTeos Therapeutics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 644,901 shares of the company's stock valued at $4,954,000 after buying an additional 4,551 shares during the last quarter. Institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.